The Clinical Implications of Key Recent Data Sets in Renal Cell Carcinoma — With Prof Thomas Powles (Proceedings from a Daylong Multitumor Symposium in Partnership with Florida Cancer Specialists)

The Clinical Implications of Key Recent Data ...

Up next

Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.CME information and select publications 

Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer. CME information and select publications here. 

Recommended Episodes

18F-PSMA-1007 PET/CT - Sponsored by Mayo Clinic
Radiology Podcast | RSNA

Dr. Ashwin Singh Parihar discusses the role of multiparametric MRI and 18F-PSMA-1007 PET/CT for the detection of clinically significant prostate cancer with Dr. Bastiaan Privé. This episode is sponsored by Mayo Clinic. Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detectio ...  Show more

Professor Joël Guigay on clinical trials of older patients with head and neck cancer
The Lancet Healthy Longevity in conversation with

Joël Guigay discusses the ELAN-FIT and ELAN-UNFIT trials in older people with head and neck cancer, published in The Lancet Healthy Longevity, and the importance of geriatric assessments in clinical trials of older cancer patients.Read the full articles: https://www.thelancet.com/ ...  Show more

AUANewsWorthy Webinar: An Integrated Biomarker and MRI Risk Assessment Approach to Prostate Cancer Diagnosis
AUANews Inside Tract

Prostate cancer diagnostic guidelines aim to minimize over-diagnosis of clinically insignificant prostate cancer (Gleason6/GG1). The clinical question before us is how do we enable the best balance, helping to increase compliance with the biopsy recommendation for patients at hig ...  Show more

A Reassessment of Prostate Cancer Treatment (Live from the 2024 ASCO Annual Meeting)
Symptomatic: A Medical Mystery Podcast

About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Join Lauren Bright Pacheco at the 2024 ASCO Annual Meeting in Chicago, as she investigates the advancements in prostate cancer care.  Dr. Mohammad Atiq shares ways innovative treatments are paving the ...  Show more